Bl-M14D1
Small Cell Carcinoma
SystImmune Inc.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Small Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hycamtin National Cancer Institute (NCI) | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II EpicentRx, Inc. | Phase 2 | BB |
ETOPOSIDE SystImmune Inc. | Phase 3 | BB |
Vinorelbine EpicentRx, Inc. | Phase 2 | BB |
Lurbinectedin SystImmune Inc. | Phase 3 | BB |
View all 31 →
Same molecule, other indications
Bl-M14D1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →